Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

References

• LeeDMWeinblattMERheumatoid arthritisLancet2001358928590391111567728
   PubMed Web of Science ®Google Scholar
• SymmonsDTurnerGWebbRThe prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new centuryRheumatology (Oxford)200241779380012096230
   PubMed Web of Science ®Google Scholar
• AlishiriGHBayatNSalimzadehAHealth-related quality of life and disease activity in rheumatoid arthritisJ Res Med Sci201116789790322279457
   PubMed Web of Science ®Google Scholar
• SmithHSSmithARSeidnerPPainful rheumatoid arthritisPain Physician2011145E427E45821927056
   PubMed Web of Science ®Google Scholar
• StrandVSharpVKoenigASComparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatmentAnn Rheum Dis20127171143115022258482
   PubMed Web of Science ®Google Scholar
• BoonenAMauWThe economic burden of disease: comparison between rheumatoid arthritis and ankylosing spondylitisClin Exp Rheumatol2009274 Suppl 55S112S11719822056
   PubMed Web of Science ®Google Scholar
• FosterWCarruthersDLipGYBlannADInflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatmentJ Thromb Thrombolysis201029443744219578810
   PubMed Web of Science ®Google Scholar
• ThwaitesCFinneyARheumatoid arthritis. 2: Exploring treatment options to achieve early control and remissionNurs Times201010610182020426296
   PubMedGoogle Scholar
• National Institute for Health and Clinical ExcellenceRheumatoid arthritis (CG79): full guidelineLondon, UKNICE2009 Available from: http://guidance.nice.org.uk/CG79/GuidanceAccessed October 30, 2012
   Google Scholar
• FriesJFSpitzPKrainesRGHolmanHRMeasurement of patient outcome in arthritisArthritis Rheum19802321371457362664
   PubMed Web of Science ®Google Scholar
• SmolenJSLandeweRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis201069696497520444750
   PubMed Web of Science ®Google Scholar
• ChenYFJobanputraPBartonPA systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectivenessHealth Technol Assess20061042iiiivxixiii1229
   Web of Science ®Google Scholar
• MaxwellLJSinghJAAbatacept for rheumatoid arthritis: a Cochrane systematic reviewJ Rheumatol201037223424520080922
   PubMed Web of Science ®Google Scholar
• Navarro-SarabiaFAriza-ArizaRHernandez-CruzBVillanuevaIAdalimumab for treating rheumatoid arthritisJ Rheumatol20063361075108116652437
   PubMed Web of Science ®Google Scholar
• BlumenauerBJuddMCranneyAEtanercept for the treatment of rheumatoid arthritisCochrane Database Syst Rev20034CD00452514584021
   PubMedGoogle Scholar
• SinghJANoorbaloochiSSinghGGolimumab for rheumatoid arthritis: a systematic reviewJ Rheumatol20103761096110420436075
   PubMed Web of Science ®Google Scholar
• BlumenauerBJuddMWellsGInfliximab for the treatment of rheumatoid arthritisCochrane Database Syst Rev20023CD00378512137712
   PubMedGoogle Scholar
• SinghJAChristensenRWellsGABiologics for rheumatoid arthritis: an overview of Cochrane reviewsSao Paulo Med J2010128530931021181074
   PubMed Web of Science ®Google Scholar
• SinghJABegSLopez-OlivoMATocilizumab for rheumatoid arthritis: a Cochrane systematic reviewJ Rheumatol2011381102020952462
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in HealthClinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid ArthritisOttawa, ONCADTH2010 Available from: http://www.cadth.ca/media/pdf/TR_RA_Clinical_and_Economic_Overview_e.pdfAccessed May 2, 2012
   Google Scholar
• ClinicalTrialsgov [homepage on the Internet]US National Institutes of Health Available from: http://clinicaltrials.govAccessed April 11, 2012
   Google Scholar
• National Institute for Health and Clinical ExcellenceAppendix D: Methodology checklist – randomised controlled trialsLondon, UKNICE2009 Available from: http://www.nice.org.uk/media/633/21/The_guidelines_manual_2009_-_Appendix_D_Methodology_checklist_-_randomised_controlled_trials.pdfAccessed October 30, 2012
   Google Scholar
• SuttonAJDuvalSJTweedieRLAbramsKRJonesDREmpirical assessment of effect of publication bias on meta-analysesBMJ200032072491574157710845965
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• HigginsJPTDeeksJJAltmanDGIntention-to-treat issues for dichotomous dataCochrane Handbook for Systematic Reviews of InterventionsChichester, UKJohn Wiley & Sons2009
   Google Scholar
• HarrisRBradburnMDeeksJJHarbordRAltmanDGSterneJMetan: fixed- and random-effects meta-analysisStata J200881328
   Web of Science ®Google Scholar
• [No authors listed]Software updates (Metan)Stata J200884594
   Google Scholar
• BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
   PubMed Web of Science ®Google Scholar
• GlennyAMAltmanDGSongFIndirect comparisons of competing interventionsHealth Technol Assess20059261134iiiiv16014203
   PubMed Web of Science ®Google Scholar
• CaldwellDMAdesAEHigginsJPSimultaneous comparison of multiple treatments: combining direct and indirect evidenceBMJ2005331752189790016223826
   PubMed Web of Science ®Google Scholar
• SuttonAAdesAECooperNAbramsKUse of indirect and mixed treatment comparisons for technology assessmentPharmacoeconomics200826975376718767896
   PubMed Web of Science ®Google Scholar
• LuGAdesAECombination of direct and indirect evidence in mixed treatment comparisonsStat Med200423203105312415449338
   PubMed Web of Science ®Google Scholar
• The BUGS project, MRC Biostatistics UnitBayesian Inference Using Gibbs Sampling (BUGS) project. WinBUGS 1.4.3 Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtmlAccessed October 30, 2012
   Google Scholar
• SpiegelhalterDJAbramsKRMylesJPBayesian Approaches to Clinical Trials and Health Care EvaluationChichester, UKJohn Wiley & Sons2004
   Google Scholar
• SuttonAJAbramsKRBayesian methods in meta-analysis and evidence synthesisStat Methods Med Res200110427730311491414
   PubMed Web of Science ®Google Scholar
• The BUGS ProjectWinbugs 1.4 beta versionNew examples for WinBUGS Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/examples.shtmlAccessed October 30, 2012
   Google Scholar
• DiasSWeltonNSuttonAAdesAENICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analyisis of randomised controlled trialsLondon, UKNICE2011 Available from: http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series(2391675).htm
   Google Scholar
• DiasSWeltonNJSuttonAJAdesAENICE DSU technical support document 5: evidence synthesis in the baseline natural history modelLondon, UKNICE2011 Available from: http://www.nicedsu.org.uk/Evidence-Synthesis-TSD-series(2391675).htm
   Google Scholar
• HasselbladVMeta-analysis of multitreatment studiesMed Decis Making199818137439456207
   PubMed Web of Science ®Google Scholar
• GelmanAPrior distributions for variance parameters in heirarchical modelsBayesian Anal200613515533
   Web of Science ®Google Scholar
• HigginsJPTDeeksJJAltmanDGSpecial topics in statistics: rare events. Studies with zero-cell countsCochrane Handbook for Systematic Reviews of InterventionsChichester, UKJohn Wiley & Sons2009
   Google Scholar
• CombeBCodreanuCFioccoUEtanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonAnn Rheum Dis200665101357136216606651
   PubMed Web of Science ®Google Scholar
• GenoveseMCMcKayJDNasonovELInterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy studyArthritis Rheum200858102968298018821691
   PubMed Web of Science ®Google Scholar
• KeystoneEHeijdeDMasonDJrCertolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum200858113319332918975346
   PubMed Web of Science ®Google Scholar
• SmolenJLandeweRBMeasePEfficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnn Rheum Dis200968679780419015207
   PubMed Web of Science ®Google Scholar
• KamedaHUekiYSaitoKEtanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trialMod Rheumatol201020653153820574649
   PubMed Web of Science ®Google Scholar
• van RielPLTaggartAJSanyJEfficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE studyAnn Rheum Dis200665111478148316464988
   PubMed Web of Science ®Google Scholar
• GenoveseMCCohenSMorelandLCombination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexateArthritis Rheum20045051412141915146410
   PubMed Web of Science ®Google Scholar
• KremerJMWesthovensRLeonMTreatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4IgN Engl J Med2003349201907191514614165
   PubMed Web of Science ®Google Scholar
• KremerJRitchlinCMendelsohnAGolimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled studyArthritis Rheum201062491792820131276
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJDouble-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum20065492817282916947782
   PubMed Web of Science ®Google Scholar
• SmolenJSBeaulieuARubbert-RothAEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialLancet2008371961798799718358926
   PubMed Web of Science ®Google Scholar
• ZhangFCHouYHuangFInfliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from ChinaInt J Rheum Dis200692127130
   Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• PfizerTEMPO CSR 36848. 24-week data, Table 9.4.2.2AData on file
   Google Scholar
• CooperNJSuttonAJLuGKhuntiKMixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillationArch Intern Med2006166121269127516801509
   PubMedGoogle Scholar
• The BUGS ProjectDIC: deviance information criterion Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/dicpage.shtmlAccessed October 30, 2012
   Google Scholar
• AbeTTakeuchiTMiyasakaNA multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritisJ Rheumatol2006331374416395748
   PubMed Web of Science ®Google Scholar
• ChenDYChouSJHsiehTYRandomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritisJ Formos Med Assoc2009108431031919369178
   PubMed Web of Science ®Google Scholar
• DurezPNzeusseu ToukapALauwerysBRA randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatmentAnn Rheum Dis20046391069107415308515
   PubMed Web of Science ®Google Scholar
• EmeryPDeodharARigbyWFEfficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE))Ann Rheum Dis20106991629163520488885
   PubMed Web of Science ®Google Scholar
• HuangFZhangFCBaoCDAdalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical studyZhonghua Nei Ke Za Zhi20094811916921 Chinese20079321
   PubMedGoogle Scholar
• KayJMattesonELDasguptaBGolimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyArthritis Rheum200858496497518383539
   PubMed Web of Science ®Google Scholar
• KeystoneECSchiffMHKremerJMOnce-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheum200450235336314872476
   PubMed Web of Science ®Google Scholar
• KimHYLeeSKSongYWA randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexateInt J Rheum Dis2007101916
   Google Scholar
• KremerJMGenantHKMorelandLWEffects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trialAnn Intern Med20061441286587616785475
   PubMed Web of Science ®Google Scholar
• LanJLChouSJChenDYChenYHHsiehTYYoungMJrA comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled studyJ Formos Med Assoc2004103861862315340661
   PubMed Web of Science ®Google Scholar
• MainiRSt ClairEWBreedveldFInfliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupLancet199935491941932193910622295
   PubMed Web of Science ®Google Scholar
• SchiffMKeisermanMCoddingCEfficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnn Rheum Dis20086781096110318055472
   PubMed Web of Science ®Google Scholar
• WeinblattMEKremerJMBankhurstADA trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med199934042532599920948
   PubMed Web of Science ®Google Scholar
• WeinblattMEKeystoneECFurstDEAdalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trialArthritis Rheum2003481354512528101
   PubMed Web of Science ®Google Scholar
• WesthovensRYocumDHanJThe safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trialArthritis Rheum20065441075108616572442
   PubMed Web of Science ®Google Scholar
• JohnsenAKSchiffMHMeasePJComparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind studyJ Rheumatol200633465966416482646
   PubMed Web of Science ®Google Scholar
• MiyasakaNClinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE studyMod Rheumatol200818325226218330677
   PubMed Web of Science ®Google Scholar
• MorelandLWSchiffMHBaumgartnerSWEtanercept therapy in rheumatoid arthritis. A randomized, controlled trialAnn Intern Med1999130647848610075615
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKStudy of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapyMod Rheumatol2009191121918979150
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaNTreatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialArthritis Rheum20045061761176915188351
   PubMed Web of Science ®Google Scholar
• van de PutteLBAtkinsCMalaiseMEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnn Rheum Dis200463550851615082480
   PubMed Web of Science ®Google Scholar
• van de PutteLBARauRBreedveldFCEfficacy and safety of the fully human anti-tumour necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II studyAnn Rheum Dis200362121168117714644854
   PubMed Web of Science ®Google Scholar
• MorelandLWBaumgartnerSWSchiffMHTreatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion proteinN Engl J Med199733731411479219699
   PubMed Web of Science ®Google Scholar
• EdwardsJCSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisN Engl J Med2004350252572258115201414
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCKlareskogLGolimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD StudyAnn Rheum Dis200968678979619066176
   PubMed Web of Science ®Google Scholar
• FleischmannRVencovskyJvan VollenhovenRFEfficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyAnn Rheum Dis200968680581119015206
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoKKawaiSTakeuchiTAzumaJLong-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension studyAnn Rheum Dis200968101580158419019888
   PubMed Web of Science ®Google Scholar
• BergmanGJDHochbergMCBoersMWintfeldNKielhornAJansenJPIndirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugsSemin Arthritis Rheum201039642544120223500
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceRheumatoid arthritis – adalimumab, etanercept and infliximab (TA130)London, UKNICE2007 Available from: http://guidance.nice.org.uk/TA130Accessed October 30, 2012
   Google Scholar
• National Institute for Health and Clinical ExcellenceRheumatoid arthritis (after the failure of previous anti-rheumatic drugs) – golimumab (TA225)London, UKNICE2011 Available from: http://guidance.nice.org.uk/TA225Accessed October 30, 2012
   Google Scholar
• TraceyDKlareskogLSassoEHSalfeldJGTakPPTumor necrosis factor antagonist mechanisms of action: a comprehensive reviewPharmacol Ther2008117224427918155297
   PubMed Web of Science ®Google Scholar
• ThorlundKDruytsEAvina-ZubietaJAWuPMillsEWhy the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomingsAnn Rheum Dis Epub October 20, 2012
   Web of Science ®Google Scholar